scholarly journals Canine Epithelial Thymic Tumors: Outcome in 28 Dogs Treated by Surgery

Animals ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 3444
Author(s):  
Marina Martano ◽  
Paolo Buracco ◽  
Emanuela Maria Morello
Keyword(s):  
Thymic Carcinoma ◽  
Late Onset ◽  
Clinical Signs ◽  
Surgical Excision ◽  
Paraneoplastic Syndromes ◽  
Survival Times ◽  
Fine Needle Aspirates ◽  
Significant Survival ◽  
Mediastinal Lymphoma ◽  
Disease Free

Thymoma is a tumor rarely reported in dogs and should be differentiated from mediastinal lymphoma. Clinical signs may have a late onset, and thymoma is often diagnosed when symptoms related to the space-occupying effect or paraneoplastic syndromes occur. CT and fine-needle aspirates or core biopsies are helpful in differential diagnosis, but flow cytometry may improve the pre-operative diagnostic ability. Concurrent paraneoplastic syndromes such as myasthenia gravis and hypercalcemia have been reported; however, their role as prognostic factors is not well determined. Surgical excision is the treatment of choice; adjuvant radiotherapy and/or chemotherapy may prolong survival in cases of incomplete excision or when a thymic carcinoma is diagnosed. Local recurrence and metastasis are infrequently reported; therefore, a long survival time is expected if the tumor is completely excised or if adjuvant therapy is undertaken. This article reports the authors’ experience with 28 dogs affected by 18 thymomas and 10 thymic carcinomas. The median overall survival in this series was 1173 days, and the median disease-free interval was 903 days. Dogs with thymic carcinoma had significantly shorter disease-free intervals and shorter, although not statistically significant, survival times. Dogs with Masaoka Stage III tumors had worse outcomes.

scholarly journals Veterinary clinical nutrition: success stories: an overview

2016 ◽  
Vol 75 (3) ◽  
pp. 392-397 ◽  
Author(s):  
Mike Davies
Keyword(s):  
Clinical Signs ◽  
Clinical Nutrition ◽  
Dietary Management ◽  
Survival Times ◽  
Success Stories ◽  
Benign Adenoma ◽  
Drug Doses ◽  
Dietary Strategies ◽  
Disease Free ◽  
Canine Osteoarthritis

In this overview of success stories in veterinary clinical nutrition topics in cats and dogs reviewed include the dietary management of chronic kidney disease, dissolution of urinary tract uroliths by dietary modification, the recognition that taurine and L-carnitine deficiencies can cause dilated cardiomyopathy; that clinical signs associated with feline hyperthyroidism (caused by a benign adenoma) can be controlled by a low-iodine diet alone; that dietary management of canine osteoarthritis can also reduce non-steroidal anti-inflammatory drug doses; and that disease-free intervals and survival times can be statistically longer in dogs with Stage III lymphoma managed with diet. As we discover more about nutrigenetics and nutrigenomics, and as we expand our basic understanding of idiopathic diseases we are bound to identify more nutritionally related causes, and be able to develop novel dietary strategies to manage disease processes, including the formulation of diets designed to alter gene expression to obtain beneficial clinical outcomes.

Feline Cutaneous Hemangiosarcoma: A Retrospective Study of 18 Cases (1998–2003)

2005 ◽  
Vol 41 (2) ◽  
pp. 110-116 ◽  
Author(s):  
Kevin P. McAbee ◽  
Lori L. Ludwig ◽  
Philip J. Bergman ◽  
Shelly J. Newman
Keyword(s):  
Surgical Excision ◽  
Tumor Location ◽  
Survival Times ◽  
Disease Free Interval ◽  
Free Interval ◽  
Complete Surgical Excision ◽  
Treatment Type ◽  
Long Term Prognosis ◽  
Disease Free

Cutaneous hemangiosarcoma (HSA) has been infrequently reported in dogs and cats. Medical records of 18 cats diagnosed with cutaneous HSA were reviewed. Age at the time of diagnosis, breed, sex, tumor location, tumor size, treatment type, survival time, disease-free interval, and cause of death were evaluated. Aggressive surgical excision of the tumor was attempted in 10 cats. A complete surgical excision was achieved in five of the 10 cats. Median survival times were statistically longer in cats that underwent surgery versus cats that did not. Cats with cutaneous HSA treated with aggressive surgical excision of their tumors may have a good long-term prognosis.

Insulinoma in the ferret: clinical findings and treatment comparison of 66 cases

1998 ◽  
Vol 34 (6) ◽  
pp. 471-475 ◽  
Author(s):  
CA Weiss ◽  
BH Williams ◽  
MV Scott
Keyword(s):  
Effective Treatment ◽  
Clinical Signs ◽  
Clinical Findings ◽  
Survival Times ◽  
Partial Pancreatectomy ◽  
Treatment Groups ◽  
Treatment Comparison ◽  
The Mean ◽  
Disease Free

The clinical signs and surgical findings were reported for 66 ferrets with insulinomas confirmed histologically. All of the ferrets were treated with one of three modalities, and disease-free intervals and survival times were gathered to determine the most effective treatment. The three treatment groups included 10 ferrets treated medically, 27 ferrets treated with pancreatic nodulectomy, and 29 ferrets treated with pancreatic nodulectomy combined with a partial pancreatectomy. The mean disease-free intervals for each group were 22, 234, and 365 days, respectively. The mean survival times for each group were 186, 456, and 668 days, respectively. Based upon the data, recommendations were made for treating insulinoma in the ferret.

Phase I Study of Fludarabine Plus Cyclophosphamide in Patients With Previously Untreated Low-Grade Lymphoma: Results and and Long-Term Follow-Up—A Report From the Eastern Cooperative Oncology Group

2000 ◽  
Vol 18 (5) ◽  
pp. 987-987 ◽  
Author(s):  
Howard S. Hochster ◽  
Martin M. Oken ◽  
Jane N. Winter ◽  
Leo I. Gordon ◽  
Bruce G. Raphael ◽  
...  
Keyword(s):  
Phase Ii ◽  
Bone Marrow Involvement ◽  
Survival Rates ◽  
Eastern Cooperative Oncology Group ◽  
Disease Free Survival ◽  
Low Grade ◽  
Survival Times ◽  
Free Survival ◽  
Disease Free

PURPOSE: To determine the toxicity and recommended phase II doses of the combination of fludarabine plus cyclophosphamide in chemotherapy-naive patients with low-grade lymphoma. PATIENTS AND METHODS: Previously untreated patients with low-grade lymphoma were entered onto dosing cohorts of four patients each. The cyclophosphamide dose, given on day 1, was increased from 600 to 1,000 mg/m2. Fludarabine 20 mg/m2 was administered on days 1 through 5. The first eight patients were treated every 21 days; later patients were treated every 28 days. Prophylactic antibiotics were required. RESULTS: Prolonged cytopenia and pulmonary toxicity each occurred in three of eight patients treated every 3 weeks. The 19 patients treated every 28 days, who were given granulocyte colony-stimulating factor as indicated, did not have undue nonhematologic toxicity. Dose-limiting toxicity was hematologic. At the recommended phase II/III dose (cyclophosphamide 1,000 mg/m2), grade 4 neutropenia was observed in 17% of all cycles and 31% of first cycles. Grade 3 or 4 thrombocytopenia was seen in only 1% of all cycles. The median number of cycles per patient was six (range, two to 11) for all patients enrolled. The response rate was 100% of 27 patients entered; 89% achieved a complete and 11% a partial response. Nineteen of 22 patients with bone marrow involvement had clearing of the marrow. Median duration of follow-up was more than 5 years; median overall and disease-free survival times have not been reached. Kaplan-Meier estimated 5-year overall survival and disease-free survival rates were 66% and 53%, respectively. CONCLUSION: The recommended dosing for this combination in patients with previously untreated low-grade lymphoma is cyclophosphamide 1,000 mg/m2 day 1 and fludarabine 20 mg/m2 days 1 through 5. The regimen has a high level of activity, with prolonged complete remissions providing 5-year overall and disease-free survival rates as high as those reported for other therapeutic approaches in untreated patients.

Advances in Medical Genetics: Huntington Disease

1987 ◽  
Vol 9 (1) ◽  
pp. 13-14
Author(s):  
Frederick Hecht
Keyword(s):  
Molecular Genetics ◽  
Huntington Disease ◽  
Age Of Onset ◽  
Late Onset ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
The United States ◽  
Medical Genetics ◽  
Clinical Signs And Symptoms ◽  
Huntington Chorea

Medical genetics is currently enjoying a time of exploration and discovery. Huntington disease has long been of interest in adult medicine. The onset of clinical signs and symptoms is usually delayed until midadulthood. It may seem strange in this context to focus on Huntington disease, but advances in molecular genetics have brought Huntington disease into the purview of pediatrics. These advances in molecular genetics make it possible to detect Huntington disease in a preclinical stage at or even before birth. The molecular approach does not replace prior approaches to Huntington disease but is synergistic and provides a model of the new genetics. Huntington disease is synonymous with Huntington chorea. It is named after George Huntington who, like his father and grandfather before him, studied the disease in families on Long Island, NY. Huntington disease is a more common hereditary disorder than phenylketonuria, which occurs in one of about 10,000 newborns in the United States. By contrast, about one in 2,000 persons is at risk for Huntington disease. Although most cases start clinically in midadulthood, usually between 35 and 42 years of age, there is great variability in age of onset. About 3% of cases are diagnosed as juvenile Huntington disease before the age of 15 years. Late onset is well known after 50 years of age.

scholarly journals The universal non-neuronal nature of Parkinson's disease: A theory

2015 ◽  
Author(s):  
André Valente ◽  
Altynay Adilbayeva ◽  
Tursonjan Tokay ◽  
Albert Rizvanov
Keyword(s):  
Gene Expression ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mitochondrial Dna ◽  
Late Onset ◽  
Clinical Signs ◽  
Global Gene Expression ◽  
Neuron Death ◽  
Hematopoietic Stem ◽  
Hematopoietic Stem Cell Niche

Various recent developments of relevance to Parkinson's disease (PD) are discussed and integrated into a comprehensive hypothesis on the nature, origin and inter-cellular mode of propagation of late-onset sporadic PD. We propose to define sporadic PD as a characteristic pathological deviation in the global gene expression program of a cell: the PD expression-state, or PD-state for short. Although a universal cell-generic state, the PD-state deviation would be particularly damaging in a neuronal context, ultimately leading to neuron death and the ensuing observed clinical signs. We review why age accumulated damage caused by oxidative stress in mitochondria could be the trigger for a primordial cell to shift to the PD-state. We put forward hematopoietic cells could be the first to acquire the PD-state, at hematopoiesis, from the disruption in reactive oxygen species (ROS) homeostasis that arises with age in the hematopoietic stem-cell niche. We argue why, nonetheless, such a process is unlikely to explain the shift to the PD-state of all the subsequently affected cells in a patient, thus indicating the existence of a distinct mechanism of propagation of the PD-state. We highlight recent findings on the intercellular exchange of mitochondrial DNA and the ability of mitochondrial DNA to modulate the cellular global gene expression state and propose this could form the basis for the intercellular propagation of the PD-state.

Dedifferentiated Liposarcoma of the Transverse Colon

2021 ◽  
pp. 000313482110545
Author(s):  
Katie Fitzgerald ◽  
Eliza M. Slama ◽  
Irina Bernescu
Keyword(s):  
Transverse Colon ◽  
Soft Tissue Sarcomas ◽  
Surgical Excision ◽  
Dedifferentiated Liposarcoma ◽  
High Grade ◽  
Nodal Involvement ◽  
Segmental Colectomy ◽  
Aggressive Tumor ◽  
Disease Free

While liposarcoma is one of the most common soft tissue sarcomas, it is rarely seen within the gastrointestinal tract, and even less frequently seen within the colon. Dedifferentiated liposarcoma is a subtype of liposarcoma, which along with the pleomorphic subtype is considered a high-grade, aggressive tumor; both possess the ability to metastasize and are associated with decreased survival. Despite complete resection, recurrence is common. While surgical excision is the cornerstone of treatment for liposarcoma of the colon, there is no consensus on adjuvant therapies. We present the case of a 66-year-old woman who presented with abdominal pain with rectal bleeding and was found on colonoscopy to have a high-grade dedifferentiated liposarcoma of the transverse colon. She underwent robotic segmental colectomy. Due to absence of nodal involvement or distal metastasis, adjuvant therapy was not administered. On 1-year follow-up, the patient remains disease free.

scholarly journals Diagnosis and management of a case of retroperitoneal eosinophilic sclerosing fibroplasia in a cat

2019 ◽  
Vol 5 (2) ◽  
pp. 205511691986717
Author(s):  
Maureen E Thieme ◽  
Anastasia M Olsen ◽  
Andrew D Woolcock ◽  
Margaret A Miller ◽  
Micha C Simons
Keyword(s):  
Abdominal Mass ◽  
Clinical Signs ◽  
Surgical Excision ◽  
Clinical Findings ◽  
Peripheral Eosinophilia ◽  
Aerobic Culture ◽  
Complete Surgical Excision ◽  
History Of ◽  
Amoxicillin Clavulanic Acid ◽  
The Masses

Case summary A 4-year-old neutered male cat was presented with a 2-month history of intermittent constipation that progressed to obstipation. Primary clinical findings included a large, multi lobulated mass in the caudodorsal abdomen, peripheral eosinophilia and hyperglobulinemia. Abdominal imaging revealed a multilobulated, cavitated mass in the sublumbar region. Exploratory celiotomy revealed multiple firm masses in the sublumbar retroperitoneal space causing ventral displacement and compression of the descending colon with extension of the masses into the pelvic canal. Histopathology was consistent with feline gastrointestinal eosinophilic sclerosing fibroplasia (FGESF). Aerobic culture was positive for Staphylococcus aureus. The cat was treated with prednisolone (2 mg/kg PO q24h), lactulose (0.5 g/kg PO q8h), amoxicillin/clavulanic acid (62.5 mg/cat PO q12h for 1 month) and fenbendazole (50 mg/kg PO q24h for 5 days). Six months postoperatively, the cat had no recurrence of clinical signs. Repeat evaluation and imaging at day 732 postoperatively revealed marked improvement of the abdominal mass, resolution of peripheral eosinophilia and no clinical signs with continued prednisolone therapy (0.5 mg/kg PO q24h). Relevance and novel information This is a report of a primary extramural FGESF lesion, and the first description of characteristics of FGESF on CT. Previous evidence suggests that the most favorable outcomes require immunosuppressive therapy and complete surgical excision; however, this case demonstrates a favorable outcome with medical management alone.

Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.

1991 ◽  
Vol 9 (7) ◽  
pp. 1151-1156 ◽  
Author(s):  
A Lipton ◽  
H A Harvey ◽  
C M Balch ◽  
C E Antle ◽  
R Heckard ◽  
...  
Keyword(s):  
Medical Center ◽  
Stage Ii ◽  
P Value ◽  
Survival Times ◽  
Bacille Calmette Guerin ◽  
Disease Free Interval ◽  
Adjuvant Immunotherapy ◽  
Corynebacterium Parvum ◽  
Free Interval ◽  
Disease Free

Two separate studies have been reported comparing Corynebacterium parvum and bacille Calmette-Guérin (BCG) as adjuvant immunotherapy for stage II melanoma patients (The Milton S. Hershey Medical Center, 48 patients; Southeastern Cancer Study Group [SECSG], 162 patients). As the criteria for patient selection and drugs used were similar, we have pooled the data to analyze the effects of these two treatments. Both studies used BCG (Tice, Chicago, IL) 3 x 10(8) live organisms per treatment by Tine technique and C parvum (Burroughs-Wellcome, Triangle Park, NC) subcutaneous at a dose of 4 mg/m2 (SECSG) or 5 micrograms/m2 (Hershey) per treatment. The only difference in these studies was the frequency of immunization, with patients in Hershey receiving 22 doses and the SECSG patients receiving 55 doses during the 2-year period of treatment. Kaplan-Meier life-table analysis for the 210 patients shows a prolonged disease-free interval for patients treated with C parvum (P = .02, two-sided Mantel procedure). In similar fashion, patients treated with C parvum had an improved survival rate (from all causes) when compared with BCG-treated patients (P = .012). An analysis of the results for the 170 patients for which the number of positive nodes was available was performed using Cox's model, with nodes as a stratification variable and with covariates of place, treatment, age, and sex. In this analysis, an observed benefit for C parvum on the disease-free interval had a P value of .37 while the benefit of C parvum on the survival times (from all causes) had a P value of .04. When the same analysis was performed using only patients aged younger than 60 years, the observed benefit of C parvum on disease-free interval had a P value of .08 and the benefit of C parvum on survival times (from all causes) had a P value of .008.

scholarly journals Syringocystadenoma Papilliferum of the Bony External Auditory Canal: A Rare Tumor in a Rare Location

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Anastasija Arechvo ◽  
Svajunas Balseris ◽  
Laura Neverauskiene ◽  
Irina Arechvo
Keyword(s):  
External Auditory Canal ◽  
Clinical Signs ◽  
Surgical Excision ◽  
Final Diagnosis ◽  
Epidermal Cyst ◽  
Syringocystadenoma Papilliferum ◽  
Rare Benign Tumor ◽  
Rare Location ◽  
Histological Characteristics ◽  
Bony Segment

Tumors originating from ceruminous glands are rare lesions of the external auditory canal. The lack of specific clinical and radiological signs makes their diagnosis challenging. We report the case of an exceptionally rare benign tumor, a syringocystadenoma papilliferum (SCAP), in an atypical location in the bony segment of the external auditory canal with uncommon clinical signs. The special traits of the case included the following: the most lateral component of the tumor was macroscopically cystic and a granular myringitis with an obstructing keratin mass plug was observed behind the mass. The clinical, audiological, radiological, and histological characteristics of the neoplasm are consequently presented. Intraoperative diagnosis of the epidermal cyst was proposed. The final diagnosis of SCAP was determined only by histological analysis after the surgical excision. The educational aspects of the case are critically discussed.

Sign in / Sign up

Export Citation Format

Share Document